Evaluation of Regulatory T Cells for Immune Hyperactivation in COVID-19 and Acute Respiratory Distress Syndrome Patients

The primary objective of this study is to evaluate the **efficacy** and **safety** of using regulatory T cells in managing **immune hyperactivation** in patients diagnosed with **COVID-19** and/or **acute respiratory distress syndrome** (ARDS). This is clinically relevant as immune hyperactivation can lead to severe complications in these conditions, and regulatory T cells may offer a novel therapeutic approach to modulate the immune response, potentially improving patient outcomes.

The clinical trial involves participants diagnosed with **immune hyperactivation in COVID-19 patients and/or acute respiratory distress syndrome**. The study population includes both male and female subjects, with an age range classified under category code 3, which typically represents adults. The trial does not focus on a vulnerable population. The sponsor has not provided information regarding the total number of participants. Selection criteria and lifestyle considerations such as diet, physical activity, or habits have not been specified. Key inclusion or exclusion criteria are not detailed in the available data.

The clinical trial is designed to evaluate the **efficacy** and safety of regulatory T cells in managing **immune hyperactivation** in patients diagnosed with COVID-19 and/or acute respiratory distress syndrome. The trial is structured as a randomized, double-blind, controlled study, ensuring that neither the participants nor the researchers know who is receiving the treatment or placebo, thus minimizing bias. The trial is expected to commence recruitment on June 30, 2023, and is projected to conclude by June 30, 2026, providing a comprehensive evaluation period.

Participants will undergo a series of study visits, beginning with an inclusion visit, which serves as a screening to determine eligibility based on predefined criteria. This visit will involve a thorough assessment of the participant's medical history and current health status. Following successful inclusion, participants will attend regular follow-up visits, which are scheduled to monitor the treatment's effects and ensure participant safety. These visits will include clinical evaluations, laboratory tests, and assessments of any adverse events. The end-of-study visit will mark the conclusion of the participant's involvement, where final evaluations will be conducted to gather data on the long-term effects of the treatment.

The expected duration of participant involvement in the trial is approximately three years, aligning with the overall trial timeline. However, certain conditions may necessitate early termination from the study, such as the occurrence of severe adverse events, non-compliance with study protocols, or withdrawal of consent by the participant. The trial's design and procedures are meticulously crafted to ensure the collection of robust and reliable data, contributing to the understanding of the treatment's potential benefits and risks in the specified patient population.

In this clinical trial, the experimental medication and non-experimental treatments have not been specified in the provided data. Therefore, a detailed description of the **experimental medication**, including its name, pharmaceutical form, dosage, route, and frequency of administration, cannot be provided. Similarly, information regarding any non-experimental treatments, such as standard-of-care therapy, placebo, or comparator treatment, is not available.

Due to the absence of specific details, additional relevant information about drug administration, dosing schedules, and participant compliance monitoring cannot be included. The trial documentation does not contain any data regarding the **pharmaceutical form** or the **dosage** of the investigational product, nor does it specify the **route of administration** or the **frequency** with which the medication should be administered. Furthermore, there is no information on whether the product is a **paediatric formulation** or if it has an **orphan drug** designation.

As the source data does not provide any information on the **maximum daily dose**, **maximum total dose**, or **maximum treatment period**, these aspects cannot be addressed. Additionally, there is no mention of any **other medicinal products** used in conjunction with the investigational drug. The absence of these details limits the ability to describe the trial's treatment regimen comprehensively.

The clinical trial is scheduled to commence recruitment on June 30, 2023, with an estimated completion date of June 30, 2026. The trial is categorized under phase 7, as per the trial category information. However, specific details regarding the efficacy assessment, such as primary and secondary endpoints, methods, and tools for measuring efficacy, are not provided in the available data. Consequently, the description of efficacy assessment parameters, including symptom improvement scores, biomarker levels, or disease remission rates, cannot be detailed. The trial's main objective, inclusion and exclusion criteria, and other relevant efficacy assessment details are also not specified in the provided information.